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It has been recently reported that treatment with an
anti-placenta growth factor (PlGF) antibody inhibits
metastasis and primary tumor growth. Here we
show that, although anti-PlGF treatment inhibited
wound healing, extravasation of B16F10 cells, and
growth of a tumor engineered to overexpress the
PlGF receptor (VEGFR-1), neutralization of PlGF
using four novel blocking antibodies had no signifi-
cant effect on tumor angiogenesis in 15 models.
Also, genetic ablation of the tyrosine kinase domain
of VEGFR-1 in the host did not result in growth inhibi-
tion of the anti-VEGF-A sensitive or resistant tumors
tested. Furthermore, combination of anti-PlGF with
anti-VEGF-A antibodies did not result in greater anti-
tumor efficacy than anti-VEGF-A monotherapy. In
conclusion, our data argue against an important
role of PlGF during primary tumor growth in most
models and suggest that clinical evaluation of anti-
PlGF antibodies may be challenging.INTRODUCTION
The VEGF pathway is important in developmental and patholog-
ical angiogenesis. The role of VEGF-A in development is under-
scored by the embryonic lethality following inactivation of a single
vegf-a allele in mice (Carmeliet et al., 1996; Ferrara et al., 1996).
VEGF-A also plays a key role in tumor angiogenesis (Ferrara
et al., 2003; Kim et al., 1993). Three VEGF pathway inhibitors
(bevacizumab, sunitinib, and sorafenib) have been approved
by the FDA as therapy for advanced cancer (Ellis and Hicklin,
2008; Ferrara et al., 2004; Kerbel, 2008). At present, there is
considerable interest in elucidating the mechanisms of refracto-
riness/resistance to anti-VEGF therapies (Ellis and Hicklin, 2008;
Ferrara, 2010).166 Cell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc.VEGF-A binds two tyrosine kinase receptors, VEGFR-1 (Flt-1)
and VEGFR-2 (KDR/Flk-1) (Ferrara et al., 2003). Although both
receptors are expressed in endothelial cells, VEGFR-1 is also
expressed in other cell types including monocytes/macro-
phages and even some tumor cells (Fischer et al., 2008). The
VEGF-A effects are primarily mediated by VEGFR-2 (Ferrara
et al., 2003). In contrast, the role of VEGFR-1 is incompletely
understood. Even though vegfr-1 null mice die in utero (Fong
et al., 1995), mice that express a VEGFR-1 lacking the tyrosine
kinase domain (flt-1 tk/ or vegfr-1 tk/ mice) are viable and
have no obvious vascular defects (Hiratsuka et al., 1998). It has
been postulated that, in this context, VEGFR-1 acts primarily
as a nonsignaling ‘‘decoy’’ for VEGF-A and potentially other
ligands (Hiratsuka et al., 1998; Park et al., 1994). However,
more recent studies indicate that, in a number of circumstances,
VEGFR-1 signaling plays a role in tumor cell growth and metas-
tasis or in pathological angiogenesis (Hiratsuka et al., 2001;
Kerber et al., 2008; Luttun et al., 2002; Shibuya, 2001; Wu
et al., 2006a; Wu et al., 2006b).
PlGF (Maglione et al., 1991) is a member of the VEGF family that
binds to VEGFR-1 but not to VEGFR-2 (Park et al., 1994). It has
been suggested that PlGF plays a role in pathological angiogen-
esis (Autiero et al., 2003), in wound healing (Carmeliet et al., 2001;
Cianfarani et al., 2006), and in the recruitment of hematopoietic
progenitors (Avecilla et al., 2004; Carmeliet et al., 2001; Hattori
et al., 2002; Luttun et al., 2002; Lyden et al., 2001). In particular,
two findings suggested a role for PlGF in tumor angiogenesis.
Although plgf/ mice did not show any obvious vascular
defects, plgf/ embryonic stem cells developed small hypovas-
cularized tumors when implanted inplgf/mice (Carmeliet et al.,
2001). Also, treatment with an anti-PlGF monoclonal antibody
(mAb) was reported to inhibit F4/80+ macrophage recruitment,
angiogenesis, and tumor growth (Fischer et al., 2007). In addition,
anti-PlGF and anti-VEGFR2 mAb DC101 were reported to have
additive effects in DC101-resistant tumors, suggesting that
anti-PlGF may be useful as an adjunct to VEGF pathway inhibitors
(Fischer et al., 2007). The VEGF-Trap (Holash et al., 2002),
a chimeric soluble receptor that blocks VEGF-A, PlGF, and
VEGF-B, is in late-stage clinical trials.
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Figure 1. Characterization of the PlGF-Blocking mAbs C9.V2 and 7A10
(A) Inhibition of PlGF-induced 67NR-VEGFR-1 cell migration by C9.V2 and 7A10 anti-PlGF mAbs.
(B) The VEGF-A-blocking abilities of two different anti-VEGF antibodies are shown as a comparison. The average numbers of migrated cells per optical field are
indicated. See Experimental Procedures for details.*p < 0.05.
(C and D) Inhibition of PlGF-induced VEGFR-1 and MAPK phosphorylation by C9.V2 and 7A10 anti-PlGF mAbs (n = 3, *p < 0.05 versus positive control. Data
represent averages of at least four independent experiments).
(E) Inhibition of biotinylated NRP-1-Fc binding to mPlGF by anti-PlGF mAbs. Anti-PlGF MAB465 is a commercial mAb from R&D Systems, mFlt1(1-3)-IgG is
a soluble VEGFR-1 variant that strongly binds PlGF. Competitive binding studies were performed in PlGF-coated plates (n = 5, data represent the average of
three independent experiments).
(A–D) Error bars represent standard deviation (SD). See also Figure S1.However, broad antitumor efficacy has not been typically
observed in previous studies employing various PlGF/VEGFR-1
pathway inhibitors. Although genetic loss of VEGFR-1 signaling
resulted in inhibition of PlGF-induced monocyte migration and
metastasis as well as reduced primary growth of tumor cells
overexpressing PlGF (Hiratsuka et al., 2001, 2002), other studies
reported that vegfr-1 tk/ background (Dawson et al., 2009a;
Hiratsuka et al., 2002) or administration of an anti-VEGFR-1
mAb (Dawson et al., 2009a; Lyden et al., 2001) does not mark-
edly affect primary growth of several tumor transplants. Further-
more, whereas VEGFR2 blockade delayed angiogenesis and
tumorigenesis in the Rip-TAG model of insulinoma, VEGFR-1
inhibition had no effect (Casanovas et al., 2005). Finally, we
have previously shown that mFlt(1-3)-IgG, a truncated soluble
VEGFR-1 construct that potently blocks VEGF-A, VEGF-B, and
PlGF (Davis-Smyth et al., 1996; Ferrara et al., 1998), has similar
antitumor efficacy to an anti-VEGF-A mAb (Shojaei et al.,
2007).We sought to re-evaluate the role of PlGF in tumor angiogen-
esis by employing multiple approaches to inhibit PlGF function.
The results presented here indicate that, independently of the
status of the VEGF-A pathway, PlGF does not play a significant
role in angiogenesis during primary tumor growth in mice.
RESULTS
Development and Characterization of Anti-PlGF mAbs
C9.V2 and 7A10
We developed a panel of anti-PlGF mAbs from hybridoma and
phage approaches and selected function-blocking candidates
with different epitope specificities (Figure S1B available online,
data not shown). These antibodies were selected for their ability
to inhibit binding of mouse PlGF-2 to VEGFR-1 in plate assays
(data not shown) and in cell-based assays (Figures 1A, 1C, 1D,
and 3C). Because there is a single PlGF isoform in mice, here-
after we will refer to mPlGF-2 as PlGF or mPlGF. 7A10 isCell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc. 167
a high-affinity, mouse-PlGF-specific rat mAb (dissociation
constant [KD] = 0.065 nM; Figure S1C, left panel) and, by cell-
based assays, has an IC50 (the concentration that results in
half-maximal inhibition) of 0.4 nM (Figure 1A). The heavy and light
chain variable regions of 7A10 were subcloned into mouse IgG2a
and kappa constant domains, respectively. The resulting
recombinant chimeric 7A10 mAb retained a nearly identical KD
and IC50 relative to the parental mAb (data not shown). 7A10
does not bind or block VEGF or hPlGF-2 (Figure S1A and data
not shown). C9.V2 is a mAb derived from a synthetic naive
human antibody phage library and is able to block both mouse
and human PlGF-2 without interfering with VEGF (Figure S1A,
right panel). The KD for this mAb is 0.9 nM (Figure S1C, right
panel), and the calculated IC50 is 0.8 nM (Figure 1 A, left panel).
The neutralizing activity and potency of these two novel anti-
PlGF antibodies were further confirmed by their ability to inhibit
PlGF-induced VEGFR-1 (Figure 1C) and MAPK phosphorylation
(Figure 1D) in VEGFR-1-overexpressing 67NR (67NR-VEGFR-1)
cells. In addition, we tested the ability of mAbs C9.V2 and 7A10
to block the interaction between PlGF and its coreceptors neuro-
pilin (NRP)-1 and NRP-2 (Gluzman-Poltorak et al., 2000; Mamluk
et al., 2002). We found that 7A10 potently blocks the interaction
between PlGF and NRP-1 (Figure 1E) and NRP-2 (Figure S1D).
As expected, based on its mPlGF KD and IC50, C9.V2 appears
to be a relatively less potent competitor of these interactions
(Figure 1E and Figure S1D).
To compare the relative potencies of these new anti-PlGF anti-
bodies with previously validated neutralizing mAbs, we took
advantage of the ability of the 67NR-VEGFR-1 cells to migrate
in response to VEGF-A or PlGF. Figures 1A and 1B show that
the relative PlGF neutralizing potency of 7A10 and C9.V2
(Figure 1A) is even greater than the VEGF-A blocking activity
of two anti-VEGF-A mAbs, G6-31 and B20-4.1 (Figure 1B).
Pharmacokinetic studies in non-tumor-bearing C57BL/6 mice
revealed that the half-lives (T1/2) for the anti-PlGF antibodies
7A10 and C9.V2 are 8.8 and 3.1 days, respectively (Figure S1F).
This is comparable to the T1/2 of 7.8 days reported for the anti-
PlGF mAb described by Fischer et al. (2007) and is also similar
to the half-lives of the two anti-VEGF-A antibodies used in this
study (data not shown). Hence, even a single dose of 50 mg/kg
of either anti-PlGF mAb is expected to cause a relatively lasting
peak of approximately 500 mg/ml in circulation (See Figure S1F).
As PlGF plasma levels are about 100 pg/ml (Fischer et al., 2007),
the expected molar excess of anti-PlGF mAb to mPlGF in circu-
lation is in the range of 1 3 106 to 1. Two additional hybridoma-
derived PlGF-blocking mAbs, 2D1 and 12D7, with KD, IC50, and
T1/2 values in between of those of 7A10 and C9.V2 were also
tested (Figures S1E–S1G and data not shown).
Anti-PlGF Treatment Does Not Result in Inhibition
of Angiogenesis or Primary Tumor Growth
We tested the ability of mAbs 7A10 and C9.V2 (30 mg/kg, three
times per week) to affect the primary growth of the LLC, TIB48,
B16F1, CT26, L1012, TIB6, and TIB42 tumor cell lines implanted
subcutaneously in Balb/c nude mice. However, with the excep-
tion of LLC, we did not find any significant differences in tumor
growth between the control mAb-treated group and the 7A10
or C9.V2 groups in any of the other tumor models tested. In168 Cell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc.contrast, anti-VEGF-A mAb (5 mg/kg twice weekly) showed effi-
cacy in most models (Figure 2A and Figures S2A–S2G).
We assessed additional anti-PlGF antibodies in tumor models
reported to be anti-PlGF sensitive (Fischer et al., 2007). We
tested the ability of anti-PlGF mAb 2D1 (50 mg/kg, three times
per week) to inhibit the growth of CT26 tumors. However, 2D1
failed to inhibit CT26 tumor growth (Figure 2B). Also, we treated
animals bearing EL4 tumors with the anti-PlGF antibodies 2D1,
12D7, or 7A10. Treatment with these mAbs (Figure 2B), or with
mAb C9.V2 (Figures 2D, 2F, 5C, and 6C), had no effect on EL4
tumor growth.
We also probed the ability of the cross-reactive anti-PlGF mAb
C9.V2 (50 mg/kg, three times per week) to affect growth of human
tumor xenografts implanted in immunodeficient mice. Figure 2C
shows that C9.V2 treatment did not inhibit growth of HM7, A673,
or HT55 tumor xenografts. We also implanted HM7 and A673
tumor cells into vegfr-1 tk/, rag2/, or rag2/ littermate
mice. However, we found no difference in tumor growth between
the two genetic backgrounds (data not shown).
To further investigate the significance of PlGF in LLC tumor
growth, we injected LLC cells in syngeneic, immunocompetent
mice. As shown in Figure 2G, in this case anti-PlGF treatment
with either C9.V2 or 7A10 mAb did not significantly inhibit tumor
growth at any of the doses tested. Consistent with these data,
LLC tumor growth was not inhibited when tumors were im-
planted in vegfr-1 tk/ syngeneic immunodeficient background
(Figure 6A). Next, we performed dose-responsive studies in
immunocompetent tumor models previously reported to be
sensitive to anti-PlGF treament (Fischer et al., 2007). Figures
2D, 2E, and 2F show that, at all doses tested, neither 7A10 nor
C9.V2 inhibited growth of B16F10, EL4, or CT26 tumors. In
contrast, anti-VEGF-A mAb G6-31 (5 mg/kg twice weekly)
resulted in significant tumor growth inhibition in all these three
models. Finally, anti-PlGF treatment had no effect on primary
tumor growth in the 66C14 and 4T1 orthotopic breast cancer
models (Figures S2H and S2I).
A proposed mechanism for PlGF-induced angiogenesis is
recruitment of VEGFR-1-positive macrophages (Fischer et al.,
2007). However, anti-PlGF did not decrease the number of
CD11+ myeloid cells in circulation (data not shown), nor did it
significantly decrease F4/80+ or CD11b+ macrophage/myeloid
cells in tumors at the end point of these studies (Figures S3A,
S3C, and S3D). In agreement with the lack of antitumor efficacy,
anti-PlGF treatment did not decrease microvascular density
(Figures S3A and S3B).
Anti-PlGF Antibodies Inhibit Wound Healing and In Vivo
Growth of 67NR Cells Overexpressing VEGFR-1
Given the lack of antitumor efficacy of our anti-PlGF mAbs, we
sough to thoroughly evaluate the ability of these reagents to
neutralize PlGF in vivo.
Loss- and gain-of-function experiments have implicated PlGF
in wound healing, especially in diabetic mice (Carmeliet et al.,
2001; Cianfarani et al., 2006). Thus, we tested the ability of
7A10 and C9.V2 to inhibit wound healing in a diabetic mouse
model. Consistent with previous observations (Cianfarani et al.,
2006), Figure 3A (left panel) shows that rPlGF accelerates wound
healing in Db/Db mice. In addition, systemic (IP) administration
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Figure 2. Anti-PlGF Treatment Does Not Inhibit Tumor Growth
(A–C) Tumor cell lines were implanted in Balbc/nude mice. Tumor weights were measured at the end of each experiment.
(A) Anti-PlGF or anti-ragweed antibodies were administered at 30 mg/kg three times wekly. Anti-VEGF-A mAb was given at 5 mg/kg twice weekly. n = 5–15,
*p < 0.05 relative to anti-ragweed treatment.
(B and C) Anti-PlGF or anti-ragweed antibodies were administered at 50 mg/kg three times per week. Anti-VEGF-A mAb was administered at 5 mg/kg twice per
week. n = 10, *p < 0.05 with respect to anti-ragweed treatment.
(D–G) Tumor cells were implanted in either balb/c (CT26 cells) orC57BL/6 (B16F10, EL4, and LLC tumor cells) mice. Dosing regimens of antibodies as indicated in
the figure.
(A–G) Antibody treatments were initiated 24 hr after tumor cell implantation. *p < 0.05 versus anti-ragweed. (A–G) Error bars represent SD. Each experiment was
repeated at least three times, with similar results. See also Figures S2 and S3.of either 7A10 or C9.2 mAb inhibited wound healing to levels
comparable to the anti-VEGF treatment (Figure 3A, right panel).
Notably, the 5 mg/kg dose had a nearly identical efficacy as
50 mg/kg (Figure S4B), suggesting that even the lower dose of
anti-PlGF is sufficient to systemically neutralize PlGF.
We considered the possibility that the lack of antitumoral effi-
cacy of anti-PlGF mAb treatment might be due to suboptimal
intratumoral delivery, degradation, and/or loss of PlGF-binding
activity. However, as shown in Figure 3B (left panel), the serum
concentrations of anti-PlGF mAb in tumor-bearing animals are
similar if not greater than those previously reported by Fisher
et al. Furthermore, at the end of these experiments, the PlGF-
blocking mAbs detected in tumor lysates were still fully func-
tional (Figure 3B, center panel) and at a vast molar excess with
respect to the estimated levels of PlGF (Figure 3B, right panel).
Moreover, the concentrations of anti-PlGF mAbs in tumors andtheir molar excess with respect to PlGF were similar or higher
than the concentrations and molar ratio of anti-VEGF mAbs in
relation to VEGF-A at maximally efficacious doses (Figure 3B,
right panel).
We also tested mAbs C9.V2 and 7A10 for their ability to inhibit
the in vivo growth of 67NR-VEGFR-1 cells. These cells proliferate
in response to PlGF in vitro (Figure 3C, left panel). As illustrated in
Figure 3C (right panel), anti-PlGF treatment inhibited growth of
67NR-VEGFR-1 tumors but had no effect on growth of 67NR
vector transduced cells. The 5 mg/kg dose had a nearly identical
efficacy as 50 mg/kg.
Anti-VEGF-A Treatment Does not Increase Intratumoral
Levels of PlGF
It has been reported that administration of the anti-VEGFR-2
mAb DC101 increases PlGF levels in circulation and PlGFCell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc. 169
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Figure 3. Anti-PlGF mAb Treatment Blocks PlGF Function In Vivo
(A) Left panel: Recombinant PlGF accelerates wound healing in Db/Db mice. Right panel: Effects of 7A10 and C9.2 anti-PlGF mAb or anti-VEGF-A in wound heal-
ing in Db/Db mice. Anti-PlGF or anti-ragweed antibodies were administered at the dose of 50 mg/kg three times per week; anti-VEGF-A was given at 5 mg/kg
twice weekly. There are no significant differences among 7A10, C9.V2, and anti-VEGF-A treatments. n = 6, *p < 0.05 compared to anti-ragweed treatment.
(B) Serum concentrations of functional anti-PlGF and anti-VEGF-A mAbs (left panel) or in tumor lysates (center panel) in treated animals. Right panel: Ratios of
anti-PlGF mAbs to PlGF and Anti-VEGF-A mAbs to VEGF-A as measured in tumor lysates of treated animals. See also Figure S4.
Functional concentrations of anti-PlGF or anti-VEGF-A mAbs were quantified by VEGFR-1 competitive binding assay as well as PlGF or VEGF-A binding assays
(see Experimental Procedures). n = 5, *p < 0.05 versus anti-VEGF-A G6-31 mAb.
(C) Left panel: Stimulation of 67NR-VEGFR-1 cell proliferation by PlGF or VEGF-A. Fold induction represents relative BrdU incorporation relative to negative
controls (n = 6, *p < 0.05 relative to the control untreated group). Right panel: 67NR-VEGFR-1 or 67NR-Vector cells were subcutaneously implanted in balb/c
mice. Figure shows the percent inhibition of tumor weight relative to anti-ragweed control groups. Antibody treatment was initiated 11 days after tumor cell
implantation. C9.V2 and 7A10 Anti-PlGF and anti-ragweed antibodies were administered three times per week. B20.4.1 anti-VEGF was dosed biweekly. Doses
of antibodies are indicated in the figure (n = 5, *p < 0.05 versus anti-ragweed).
Experiments were repeated three times with similar results. Error bars represent SD.mRNA in tumors (Fischer et al., 2007). However, we found that, in
contrast to DC101, anti-VEGF treatment does not increase PlGF
levels in circulation (Figure 4A and data not shown). We also
found that DC101 treatment increases plasma PlGF levels in
non-tumor-bearing mice (data not shown), suggesting that this
is a systemic response that occurs regardless of tumor implan-
tation. We then measured the intratumoral PlGF concentrations
during anti-VEGF-A or anti-ragweed treatment. Figure 4B shows
that anti-VEGF-A treatment does not increase PlGF protein
levels in any of the tumor models evaluated. Furthermore, as
shown in Figure 4C, VEGF-A blockade with either G6-31,
B20.4.1, and even DC101 mAb does not increase PlGF protein
levels in CT26 tumor lysates.170 Cell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc.Blocking VEGF-A and PlGF Does Not Result in Greater
Efficacy than Anti-VEGF-A Monotherapy
We investigated whether PlGF blockade might enhance the
response to VEGF-A inhibition in models previously described
as resistant to VEGF pathway inhibitors, such as CT26, EL4,
and LLC (Fischer et al., 2007; Shojaei et al., 2007). We found
that anti-VEGF-A treatment inhibits CT26 tumor growth more
completely than DC101 (Figure 5A). Consequently, we tested
the EL4 and LLC models, which show only a partial inhibition
by anti-VEGF-A (Figures 2F and 2G; Shojaei et al., 2007). First
we tested the efficacy of mFlt(1-3)-IgG, a soluble VEGFR-1
variant that inhibits PlGF, VEGF-A (Figure S5), and VEGF-B
and suppresses tumor growth in vivo (Gerber et al., 2000).
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Figure 4. Anti-VEGF-A Treatment Does Not Increase PlGF Levels
(A) PlGF concentrations in plasma from CT26 tumor-bearing mice. Plasma samples were collected at the end point of this study (day 24). n = 5, *p < 0.05 versus
anti-ragweed.
(B) PlGF concentrations in tumor lysates. Tumors were collected at the end of each study: day 24 for CT26, day 15 for EL4, day 21 for LLC, and day 20 for B16F10.
n = 5. CT26 was implanted in balb/c mice, and El4, LLC, and B16F10 in *p < 0.05 versus anti-ragweed.
(C) PlGF concentrations in CT26 tumor lysates. Samples were collected at the end point of the study (day 24). Tumors were implanted in balb/c mice. n = 5,
*p < 0.05 versus anti-ragweed.
(A–C) PlGF concentrations were measured by ELISA. Antibodies were administered at the dose of 50 mg/kg for DC101 (twice a week), 7A10, C9.V2, and anti-
ragweed (three times per week) and at 5 mg/kg biweekly for B20.4.1 and G6-31 anti-VEGF-A mAbs. Error bars represent SD.Consistent with previous studies (Shojaei et al., 2007), the effi-
cacy of mFlt1(1-3)-IgG was equivalent to that of anti-VEGF-A
mAb (Figures 5B and 5C). To further corroborate these findings,
we treated tumor-bearing mice with combinations of anti-PlGF
mAbs 7A10 or C9.V2 and anti-VEGF mAb G6-31. As shown in
Figures 5B and 5C, PlGF neutralization did not enhance the anti-
tumor efficacy of anti-VEGF-A.
PlGF Blockade and/or Genetic Inhibition of Host
VEGFR-1 Tyrosine Kinase Signaling Does Not Enhance
the Antitumor Effects of Anti-VEGF
We examined whether lack of host VEGFR-1 signaling might
sensitize tumors to anti-VEGF-A treatment. We implanted the
anti-VEGF-A refractory tumor cell lines LLC and EL4 in the
vegfr-1 tk/ and wild-type (WT) backgrounds. As shown in
Figures 6A and 6B, lack of host VEGFR-1 TK signaling activity
did not inhibit primary growth of LLC and EL4 tumors. Further-
more, the vegfr-1 tk/ background also failed to inhibit primary
tumor growth of HM7, A673, and B16F10 (data not shown
and Figure 7A). This lack of significant inhibition of primary
tumor growth upon VEGFR-1 signaling blockade is consistent
with previously published data (Dawson et al., 2009a, 2009b;
Hiratsuka et al., 2002; Kaplan et al., 2009; Lyden et al., 2001).
We then evaluated the effects of combining vegfr-1 tk/ defi-
ciency with VEGF-A blockade. As shown in Figures 6A and 6B,
there were no significant differences in tumor growth between
anti-VEGF mAb-treated WT and vegfr-1 tk/ in LLC (Figure 6A)
and EL4 (Figure 6B) tumor-bearing mice. Although these findings
do not rule out the possibility that VEGFR-1 signaling plays a role
in tumor angiogenesis in other models (Hiratsuka et al., 2001;
Kerber et al., 2008; Marcellini et al., 2006; Wu et al., 2006a),
they indicate that genetic ablation of this pathway in the stromal
compartment does not generally sensitize anti-VEGF-A refrac-
tory tumors to respond to VEGF-A blockade.We next tested whether combining PlGF blockade with loss of
VEGFR-1 signaling might increase the antitumor efficacy of anti-
VEGF treatment. As shown in Figure 6C, neither mFlt1(1-3)-IgG
nor anti-PlGF 7A10 plus anti-VEGF G6-31 nor anti-PlGF C9.V2
plus anti-VEGF mAb G6-31 augmented the efficacy of anti-
VEGF monotherapy in EL4 tumors implanted in vegfr-1 tk/
mice. In addition, Figure 6D shows that tumor responses to the
different treatments studied here are nearly identical in WT and
vegfr-1 tk/ backgrounds.
PlGF Blockade or Genetic Ablation of Host VEGFR-1
Signaling Reduces B16F10 Cell Extravasation to the
Lungs but Does Not Inhibit Primary Tumor Growth
VEGFR-1 and PlGF have been previously implicated in the meta-
static spread of B16 melanoma cells (Fischer et al., 2007; Hirat-
suka et al., 2002; Kaplan et al., 2005, 2009; Marcellini et al.,
2006). In addition, Fisher et al. reported that blockade of PlGF
inhibits B16F10 primary tumor growth. However, genetic loss
of host vegfr-1 tk (Dawson et al., 2009a; Hiratsuka et al., 2002),
administration of an anti-VEGFR-1 mAb (Dawson et al., 2009a;
Lyden et al., 2001), or VEGFR-1 knockdown in bone marrow-
derived cells (Kaplan et al., 2009) did not markedly affect primary
growth of B16 tumors. In agreement with these data, we found
that inhibition of PlGF with two different mAbs (Figure 2E) or
genetic loss of host VEGFR-1 TK signaling (Figure 7A) does not
result in significant inhibition of B16F10 primary tumor growth.
However, loss of VEGFR-1 TK signaling significantly decreased
the number of intravenously injected B16F10 cells that establish
metastatic nodules in the lungs (Figure 7B). These data suggest
that VEGFR-1 signaling plays a role in B16F10 cell extravasation,
and that blockade of PlGF or VEGF-A might have antimetastatic
effects in this model. Indeed, neutralization of PlGF with either
C9.V2 or 7A10 anti-PlGF mAb or anti-VEGF-A mAb B20.4.1
reduced the number of B16F10 nodules in the lung (Figures 7CCell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc. 171
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A Figure 5. Blockade of VEGF-A and PlGF(and VEGF-B) Does Not Result in Greater
Tumor Growth Inhibition than Anti-VEGF
Monotherapy
(A) CT26 tumors were implanted in balb/nude
mice. Antibody treatments were initiated 24 hr after
tumor cell implantation. n = 10, *p < 0.05 versus
anti-ragweed treatment; *p < 0.05 versus anti-
VEGFR-2 (DC101); *p < 0.05 versus anti-ragweed.
(B) LLC and (C) EL4 cells were subcutaneously
implanted in C57BL/6 mice (n = 10); *p < 0.05
versus anti-ragweed. Not significant (NS), p >
0.05 versus anti-VEGF-A treatment; *p < 0.05
versus anti-ragweed.
(A–C) Experiments were repeated three times, with
similar results. Error bars represent SD. See also
Figure S5.and 7D). Importantly, the 5 mg/kg dose of anti-PlGF 7A10 was
sufficient to achieve maximal inhibition (Figure 7D). However,
the volume of individual metastases was not significantly
affected by anti-PlGF treatment (data not shown). These data
are consistent with the hypothesis first proposed by Hiratsuka
et al. that PlGF/VEGFR-1 signaling is primarily involved in facili-
tation of tumor migration or invasion rather than in tumor angio-
genesis (Hiratsuka et al., 2002; Kaplan et al., 2005).
DISCUSSION
PlGF was identified 19 years ago (Maglione et al., 1991), but the
significance of this molecule is still a matter of debate. Notably,
studies addressing the role of PlGF in various models yielded
conflicting results. Some investigators reported that PlGF has
potent mitogenic and angiogenic effects (Odorisio et al., 2002;
Ziche et al., 1997), while others were unable to document such
effects (Cao et al., 1996; Park et al., 1994). PlGF overexpression
enhanced tumor growth in some models (Hiratsuka et al., 2001;
Marcellini et al., 2006), but in others PlGF paradoxically had an
inhibitory effect, presumably through formation of VEGF/PlGF
heterodimers, which can downregulate VEGFR2 signaling (Eriks-
son et al., 2002; Schomber et al., 2007).
Recently, Fisher et al. reported that treatment with an anti-
PlGF mAb has antiangiogenic effects during primary tumor
growth in all tumor models tested. However, the same group
subsequently reported that genetic ablation of PlGF has no
effect on the growth of pancreatic islet tumors in the RIP-Tag
model (Fischer et al., 2008). Here we show that neutralization
of PlGF, genetic ablation of host PlGF receptor signaling, or
combined anti-PlGF treatment and loss of host VEGFR-1 TK
signaling do not inhibit angiogenesis during primary tumor
growth. This lack of efficacy was observed with various reagents
and most tumor models tested in immunodeficient and immuno-172 Cell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc.competent animals. Importantly, despite
the lack of antitumor efficacy, the novel
anti-PlGF antibodies used in the present
study blocked endogenous PlGF sig-
naling, as demonstrated by their ability
to inhibit (1) wound healing in Db/Dbmice, (2) growth of VEGFR-1-overexpressing tumors, and
(3) B16F10 cell extravasation to the lungs.
Although in three independent experiments we observed an
30% inhibition of LLC tumor growth by anti-PlGF treatment in
the balb/c nude background (Figure 1A), the same treatment
failed to inhibit LLC growth when tumor cells were implanted in
a syngeneic C57 black 6 background (Figure 2G). Although the
reasons for such discrepancy remain unclear, it is possible that
the efficacy of anti-PlGF in the context of allogenic LLC tumors
reflects modulation of innate immune responses (Hattori et al.,
2002; Murakami et al., 2006), rather than inhibition of angiogen-
esis. In this context, it is noteworthy that genetic inhibition of host
VEGFR-1 TK signaling (Dawson et al., 2009a; Hiratsuka et al.,
2002) or anti-VEGFR-1 treatment (Dawson et al., 2009a; Lyden
et al., 2001) did not inhibit LLC primary growth in syngeneic
mice.
Interestingly, 67NR-VEGFR-1 but not the control 67NR-vector
tumors were growth-inhibited by anti-PlGF treatment. However,
the 67NR-VEGFR-1 cells overexpress VEGFR-1 and do prolif-
erate in response to PlGF stimulation (Figure 3C, left panel).
Therefore, the responsiveness of 67NR-VEGFR-1 tumors to
anti-PlGF is likely due to direct inhibition of VEGFR-1 signaling
in tumor cells rather than inhibition of angiogenesis. Neverthe-
less, these findings raise the possibility that anti-PlGF, similar
to anti-VEGFR-1 mAb (Wu et al., 2006a, 2006b), may be useful
for inhibiting growth of VEGFR-1 signaling-dependent tumors.
PlGF and VEGFR-1 have been previously implicated in
B16 metastasis (Fischer et al., 2007; Hiratsuka et al., 2002;
Kaplan et al., 2009; Marcellini et al., 2006). Therefore, we tested
the ability of our anti-PlGF antibodies to inhibit B16F10 cell
extravasation into the lungs. Our results confirm the involvement
of PlGF and VEGFR-1 signaling in regulating B16F10 metastasis
under the experimental conditions tested. We believe that
these are true ‘‘on-target’’ effects, based on the following
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Figure 6. Loss of Host VEGFR-1 TK Signaling Does Not Affect Tumor Growth, in the Presence or Absence of VEGF Inhibition
LLC (A) and EL4 (B) cells were subcutaneously implanted in either vegfr-1 tk/ mice or WT C57BL/6 littermates (n = 10, NS p > 0.05 versus wt). Anti-VEGF-A and
anti-ragweed Abs were given at 5 mg/kg biweekly.
(C) EL4 cells were implanted in vegfr-1 tk/ mice. n = 10, *p < 0.05 versus anti-ragweed. NS, p > 0.05 versus anti-VEGF-A treatment.
(D) Compared towt, the vegfr-1 tk/ background does not affect the efficacy of anti-PlGF or anti-VEGF-A mAbs in single or combination treatments. n = 10, NS >
0.05, flt tk/ versus wt. Data shown are combined from Figures 5C and 6C.
(A–D) Experiments were repeated at least three times, with similar results. Error bars represent SD.observations: (1) similar anti-metastatic effects were obtained
with two independent antibodies; (2) maximal inhibition was
achieved at a low dose of antibodies, consistent with the high
binding affinity of these reagents; (3) genetic inhibition of host
VEGFR-1 TK signaling also inhibited B16F10 lodging. These
findings raise the possibility that anti-PlGF may have a role as
an antimetastatic treatment. However, very recent studies
suggest that the role of VEGFR-1 signaling in metastasis is, at
least in part, model or context dependent (Dawson et al.,
2009a, 2009b; Kaplan et al., 2009). Indeed, we found that anti-
PlGF mAb treatment does not inhibit metastasis in an orthotopic
model (data not shown). Further studies are needed to address
these issues.
The reasons for the discrepancies between our data and the
results published by Fisher et al. are currently unknown.
However, it is important to note that the conclusions of these
authors were based on testing a single PlGF-blocking reagent.
In contrast, the conclusions of this manuscript rely on the effects
of four different anti-PlGF mAbs, genetic disruption of host PlGF
receptor signaling, combination of both, or blockade of all
VEGFR-1 ligands with mFlt(1-3)-IgG. Thus, the cumulative data
presented here indicate that the efficacy of Fisher’s anti-PlGF
mAb is possibly due to off-target effects. Indeed, off-targeteffects are not uncommonly observed in the presence of high
doses of certain monoclonal antibodies. Furthermore, not only
have the Fc domains of some IgGs been previously shown to
trigger anti-inflammatory reactions, but Fc-induced citotoxicity
has also been previously implicated in the antitumor efficacy of
known therapeutic antibodies (Clynes et al., 2000; Oflazoglu
et al., 2007; Samuelsson et al., 2001). In this context, the dose-
response curve for the effects of anti-PlGF mAb, showing that
a maximal effect requires the dose of 50 mg/kg, is surprising.
At this dose, Fisher et al. reported a very large excess of antibody
with respect to PlGF, at least in the plasma (approx. 1.8 3 106
to 1) (Fischer et al., 2007). Taking also into account the reported
high binding affinity of this mAb for PlGF, the finding that only a
2-fold lower dose was not maximally efficacious is unexpected
(Fischer et al., 2007). In contrast, anti-PlGF mAbs with compa-
rable affinity and pharmacokinetic characteristics had no signif-
icant effect on primary tumor growth even at the highest dose
tested, even though they inhibited metastasis, wound healing,
and growth of VEGFR-1-expressing tumors with a maximal
effect at doses as low as 5 mg/kg.
In conclusion, we have provided multiple lines of evidence
indicating that PlGF blockade does not result in inhibition of
primary tumor growth in most models. While we cannot ruleCell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc. 173
Figure 7. PlGF Blockade or Genetic Ablation of Host VEGFR-1 Signaling Inhibits B16F10 Metastasis
(A) Genetic loss of host VEGFR-1 TK signaling does not inhibit B16F10 primary tumor growth.
(B) Lack of host VEGFR-1 TK signaling inhibits lung extravasation of intravenously injected B16F10 cells.
(C) Anti-PlGF treatment with C9.V2 or 7A10 mAb inhibits lung extravasation of B16F10 cells. Left panel: Numbers of metastatic nodules as determined by surface
counting under the microscope. Right panel: Representative images of lung metastasis acquired by Micro Computer Tomography (micro-CT). Surface counting
and micro-CT quantification of metastatic nodules gave comparable results.
(D) Maximal antimetastatic activity was achieved with 5 mg/kg of anti-PlGF mAb 7A10.
(A–D) 13 104 B16F10 cells were injected in the tail vein of C57BL/6 or vegfr-1 tk/mice. Animals were given 5, 20, or 50 mg/kg of anti-PlGF 7A10 Ab (three times
per week); 50 mg/kg of anti-PlGF C9.V2 or anti-ragweed Ab (three times per week), or 5mg/kg of anti-VEGF B20.4.1 (biweekly). Metastatic nodules in the lungs
were quantified 2–3 weeks after cell injection. Experiments were repeated at least three times, with similar results. Error bars represent SD.out the possibility that PlGF inhibition may have different effects
in tumor models that we did not test, our findings argue against
broad antiangiogenic or antitumor efficacy in anti-VEGF-resis-
tant tumors. In this context, it is intriguing that a phase III
study in pancreatic cancer patients, testing the VEGF-Trap in
combination with gemcitabine, was recently stopped following
the determination that, similar to bevacizumab, such treatment
would not increase survival relative to gemcitabine alone
(reviewed in Ferrara, 2010). These findings indicate that, at least
in this circumstance, the simultaneous inhibition of VEGF-A and
PlGF (and VEGF-B) does not confer enhanced tumor suppres-
sion relative to specific VEGF-A blockade.
EXPERIMENTAL PROCEDURES
Cell Migration Assay
Migration assays were performed in transwell membranes (8 mm pore size)
inserted in 24-well plates (Corning Costar). Membranes were coated with174 Cell 141, 166–177, April 2, 2010 ª2010 Elsevier Inc.a solution of 10 mg/ml collagen type I (BD) in PBS for 1 hr at 37C, then washed
and air-dried before use. 67NR-VEGFR-1 cells were grown in IMDM containing
10% fetal bovine serum (FBS) until they were 80% confluent and then starved
in serum-free IMDM for 5 hr. Cells where then trypsinized and plated into
migration inserts (20000 cells/insert in IMDM). PlGF or VEGF (R&D, Minneap-
olis, MN, USA) was added to the lower wells filled with IMDM containing
different concentration of the corresponding mFlt-1(1-3)-IgG, anti-VEGF-A,
or anti-PLGF mAb. The plates were incubated for 18 hr at 37C. Cells on the
top of the membrane were carefully wiped off. Cells on the bottom of the
membrane were fixed with 100% ethanol for 5 min and stained with hematox-
ylin for 10 min and then rinsed off gently with running water. The number of
migrated cells in each well was then quantified by counting 5 randomly chosen
fields at 1003 magnification. Each determination represents the mean of 3
individual wells ± standard deviation (SD). Experiments were repeated at least
three times.
Cell Proliferation Assay
DNA synthesis was determined by measuring BrdU incorporation with the Cell
Proliferation ELISA System (Cell Proliferation ELISA, BrdU chemilumines-
cence. Roche, Indianapolis, IN, USA). Briefly, cells were seeded in 96-well
culture plates at a density of 2 3 103 cells/well. Twenty-four hours after
seeding, cells were starved for 3 hr, then stimulated with rmPLGF (from
R&D) 10 ng/ml, mPLGF 50 ng/ml plus aPLGF C9.V2 and 7A10 (10 mg/ml),
rmVEGF (From R&D) 50 ng/ml, and rmVEGF 50 ng/ml plus mAb G6-31
10 mg/ml for 60 hr. After 60 hr, medium was removed and the cells were incu-
bated for 2 hr with a BrdU labeling solution containing 10 mM BrdU. The assay
was performed according to the manufacturer’s instructions. Culture medium
alone was used as a control for nonspecific binding.
VEGFR-1 Phosphorylation Assay
67NR cells (6 3 106 per 10 cm dish) were grown in Iscove’s Modified Dulbec-
co’s Medium (IMDM, GIBCO) with 10% FBS until 80% to 90% confluent. After
5 hr serum starvation, cells were stimulated with PlGF 50 ng/ml, PLGF 50 ng/ml
plus aPLGF C9, or 7A10 (10 mg/ml), VEGF 50 ng/ml, VEGF 50 ng/ml plus
aVEGF G6 10 mg/ml, control IgG aRagweed 10 mg/ml. After 10 min, the cells
were lysed in cell lysis buffer (Cell Signaling Technology, Beverly, MA, USA)
containing Phosphatase Inhibitor Cocktail 1 1:100 dilution and PMSF 1 mM
(Sigma, St. Louis, MO, USA). The cell lysates were centrifuged at 13,000g
for 10 min at 4C, and the resulting supernatant was incubated with FLT-1 anti-
body (2 mg/ml) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) over-
night at 4C. Immunocomplexes were captured by incubating with EZview
Red Protein A Affinity Gel (Sigma) and immunoprecipitated proteins were sub-
jected to immunoblotting analysis using a p-Tyr(PY99) mAb (1:2000 dilution)
(Santa Cruz Biotechnology, Inc.). Proteins were visualized by using an ECL
kit. For total VEGFR-1, blots were reprobed with an anti-FLT-1 antibody
(1:500 dilution) (R&D).
PlGF/NRP1 and PlGF/NRP2 Competition Binding Assay
Microtiter plates (Nunc, Rochester, NY, USA) were coated with recombinant
mouse PlGF (BioVision, Mountain View, CA, USA) either at 2 mg/ml (for PlGF/
NRP1 binding) or at 4 ug/ml (for PlGF/NRP2 binding) in PBS. After an overnight
incubation at 4C, assay plates were washed with wash buffer (PBS/0.05%
Tween 20) and treated with block buffer (PBS/0.5% BSA) for 1 to 2 hr. Samples
were serially diluted in sample diluent (PBS/0.5% BSA/15ppm Proclin/0.05%
Tween 20/0.2%BGG/0.25% CHAPS/5 mM EDTA/0.3 M NaCl, pH 7.4) contain-
ing 0.25 mg/ml of heparin (Sigma) and incubated in the presence of either
100 ng/ml of biotin-mouse NRP1-Fc (0.66 nM for PlGF/NRP1 binding) or
425 ng/ml of biotin-NRP2-Fc (6 nM for PlGF/NRP2 binding). After incubation
for 2 hr, assay plates were washed six times with wash buffer and then incu-
bated for 45 to 60 min with AMDEX streptavidin-HRP (GE Healthcare, Pitts-
burgh, PA, USA) diluted 10,000-fold in assay buffer (PBS/0.5% BSA/0.05%
Tween 20, pH 7.4). After washing (six times), detection step was carried on
using tetramethylbenzidine (TMB) substrate (Moss Inc., Passadena, MD,
USA). Absorbance was measured at 450 nm against a reference wavelength
of 620 nm.
Subcutaneous Tumor Models
Tumor cells (1 3 106) were subcutaneously inoculated in the dorsal flank of
mice of different genotypes, as indicated in the figures. Antibodies were IP
injected at the doses indicated in the corresponding figure legends. Treat-
ments with the anti-PlGF mAbs described in this manuscript or with anti-
VEGF mAb G6-31 or B-20.4.1 (Liang et al., 2006) were initiated 24 hr after
tumor cell inoculation. For syngeneic tumor models, EL4, LLC, and B16F10
cells were implanted in C57BL/6 mice, while CT26 cells were implanted in
balb/c mice. All tumor growth experiments were performed at least three times
and conducted in accordance with the Guide for the Care and Use of Labora-
tory Animals. An Institutional Animal Care and Use Committee (IACUC)
approved all animal protocols.
Wound Healing Assay
Eight-week-old female C57BL/6 or Db/Db mice were used in this study. The
indicated doses of antibodies were administered at day 4 and day 2 and
then every other day from day 0 until day 10. Circular wounds of 6 mm diameter
were generated at the scapular region of anesthetized females by excising skin
and the subcutaneous fat and muscle panniculus carnosus using a punch
(Stiefel, Olfenbach, Germany). Each group consisted of six mice. Macroscopic
wound closure was determined by measuring the wound area until day 28. Theexperiments were conducted in accordance with the Guide for the Care and
Use of Laboratory Animals, published by the NIH (NIH Publication 85-23,
revised 1985). An Institutional Animal Care and Use Committee (IACUC)
approved all animal protocols.
B16F10 Metastasis
B16F10 cells (1 3 104) were injected in the tail vein of C57BL/6 or flt-1 tk/
mice. Shortly after tumor cell inoculation, animals were treated with anti-
PlGF mAb 7A10 (5, 20, 50 mg/kg) or C9.V2 (50 mg/kg). Antibodies were
administered thereafter three times per week. Anti-VEGF mAb B20.4.1 was
administered twice weekly at the dose of 5 mg/kg. two to three weeks after
tumor cell injection, lungs were washed, inflated, and subsequently collected.
Lung preparations, imaging, and analysis were conducted as described in the
Extended Experimental Procedures. Metastatic nodules were counted in
a blinded fashion by superficial counting under the microscopy and/or by
quantification of Micro-CT acquired images. Both methods gave similar
results. All the metastasis experiments were repeated three times and con-
ducted in accordance with the Guide for the Care and Use of Laboratory
Animals. An Institutional Animal Care and Use Committee (IACUC) approved
all animal protocols.
Flow Cytometry
Bone marrow mononuclear cells (BMNCs), peripheral blood mononuclear cells
(PBMNCs), and tumor cells were harvested from mice implanted with tumors.
Red blood cells were lysed using ACK (Cambrax) lysis buffer, followed by
staining with rat anti-mouse CD11b (Myletnyi Biotech) conjugated with
allophycocyanin (APC). To exclude dead cells, 7AAD (aminoactinomycin D;
BD Biosciences, San Diego, CA, USA) was added to all samples before data
acquisition in the FACS instrument (BD Biosciences).
Animals and Cell Lines
Female C57BL/6, BALB/c, and BALB/c nude were obtained from Charles River.
RAG2/ mice were from Jackson labs. flt tk/ mice were generated as
described (Hiratsuka et al., 1998). flt-1 tk, rag2 double ko mice were generated
by crossing flt-1 tk/ with rag2/ mice. Cell lines were obtained from ATCC.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures and
five figures and can be found with this article online at doi:10.1016/j.cell.
2010.01.033.
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